3 March 2023
NSAIDs in Pregnancy (3.3.2023)

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow.  This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.

  1. Study of 87 pts with isolated Nail Psoriasis noted that 11% went on to have #PsA (concurrently or within 3 years). NP findings were mainly onycholysis in79% and nail pitting in 70% https://wb.md/3YaS6VK

51 Juvenile SLE (j-SLE) studied for neuropsychiatric Dz (j-NPSLE)- 39% presented with jNPSLE. While no clear biomarker/i

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
51 Juvenile SLE (j-SLE) studied for neuropsychiatric Dz (j-NPSLE)- 39% presented with jNPSLE. While no clear biomarker/imaging of j-NPSLE identified, they found CSF neopterin (& IFN-α) levels signif higher w/ active j-NPSLE & CNS involvement (p=0.0008) https://t.co/QM8yJGrBJu https://t.co/4hj1eE2JIC
Links
https://bit.ly/3ZwhLcl

Study of 87 pts with isolated Nail Psoriasis noted that 11% went on to have #PsA (concurrently or within 3 years). NP fi

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Study of 87 pts with isolated Nail Psoriasis noted that 11% went on to have #PsA (concurrently or within 3 years). NP findings were mainly onycholysis in79% and nail pitting in 70% https://t.co/2NynITxe6B https://t.co/qs4uYySjxp
Links
https://wb.md/3YaS6VK

QD Clinic - Double Positive, but Few Joints

QD Clinic - Recurrent Fevers; 3 Days at 103F

2 March 2023
VEGA - The Efficacy of Combination Biologics in Ulcerative Colitis

A novel trial has shown that combination biologic therapy (guselkumab plus golimumab) to be more effective in ulcerative colitis than either biologic alone.

PsA: Depressing News on Second- and Later-Line Treatments Most patients with PsA failed to achieve low disease activit

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
PsA: Depressing News on Second- and Later-Line Treatments Most patients with PsA failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated. https://t.co/7tSzoNLVoD https://t.co/3oUM4E38b1
Links
https://bit.ly/3IZAHeg

Treat-to-Target Guidelines for GCA and PMR The Annals of Rheumatic Disease has published updated multinational, T2T rec

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Treat-to-Target Guidelines for GCA and PMR The Annals of Rheumatic Disease has published updated multinational, T2T recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). https://t.co/OQmtqGGNQu https://t.co/eEOTWfdgLI
Links
https://bit.ly/3IFndCR

Prospective study of 490 mod-to-severe psoriasis compared prospectively by exam & US for PsA - 384 w/o arthritis (Si

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Prospective study of 490 mod-to-severe psoriasis compared prospectively by exam & US for PsA - 384 w/o arthritis (Silent PSO), 80 non-PSO & 106 w prodromal or active PsA (12.7%). US synovio-enthesitis in 1.8% of controls & 16.1% of silent PSO (p< 0.001) https://t.co/kUdIwLnfYL https://t.co/dgIaOXaJKR
Links
https://bit.ly/3J7vctZ
Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×